REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Joint Regeneration Stack

Recovery & Healingintermediate

85

synergy

85
Share
Peptides

3

Avg Daily mcg

3,500

Level

intermediate

Added

May 17, 2026

Overview

The Joint Regeneration Stack builds upon the foundational Wolverine Stack by adding GHK-Cu (Glycyl-L-Histidyl-L-Lysine copper complex), a naturally occurring tripeptide-copper complex that declines significantly with age. GHK-Cu is one of the most studied peptides for tissue remodeling, with over 60 published studies demonstrating its ability to stimulate collagen synthesis, attract immune cells to sites of damage, promote glycosaminoglycan production, and modulate metalloproteinase activity — all critical processes for joint cartilage maintenance and repair. BPC-157 contributes its characteristic angiogenic and growth-factor-modulating properties, creating improved blood supply to hypovascular joint tissues such as cartilage and menisci, which normally receive limited circulation. TB-500 provides systemic anti-inflammatory effects and promotes cellular migration, ensuring repair cells can reach deep joint structures. The addition of GHK-Cu specifically targets the extracellular matrix remodeling that is essential for cartilage and synovial tissue regeneration. The three-peptide synergy addresses joint degeneration from multiple angles simultaneously: BPC-157 restores vascular supply and growth factor signaling, TB-500 reduces chronic inflammation and enables cellular trafficking, and GHK-Cu directly stimulates the synthesis of collagen type II, proteoglycans, and other structural components of articular cartilage. This makes the stack particularly suitable for individuals with degenerative joint conditions, chronic tendinopathy, or those recovering from joint injuries where simple rest and anti-inflammatories have proven insufficient. The intermediate classification reflects the three-compound complexity and the need for consistent dosing across different schedules.

Dosing Protocol

BPC-157

Twice per day· subcutaneous

Read more about BPC-157 →

250 mcg

per dose

TB-500

2x/week· subcutaneous

Read more about TB-500 →

2,500 mcg

per dose

GHK-Cu

Every day· subcutaneous

Read more about GHK-Cu →

500 mcg

per dose

Goals & Evidence

Joint repairCartilage regenerationInflammationCollagen synthesisMobility
Evidence tier:Animal Studies

Warnings

  • BPC-157 and TB-500 are FDA Category 2. GHK-Cu is Category 1 (legal to compound).

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.